4:50 PM
Jan 04, 2019
 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives (see "AZ's Mallon to Lead Ironwood; Hecht to Helm Spinout"; "Immunocore Taps MedImmune's Jallal as CEO").

Here's BioCentury Extra's roundup in alphabetical order:

Cancer company Adastra Pharmaceuticals Inc. (Princeton, N.J.), which changed its name from Tragara Pharmaceuticals Inc. on Jan. 3, hired Scott Megaffin as CEO and a director. Megaffin replaces Tom Estok, who remains a director. Megaffin was president of Churchill Pharmaceuticals LLC (King of Prussia, Pa.).

Metabolic disease company Allena Pharmaceuticals Inc. (NASDAQ:ALNA) will promote President and COO Louis Brenner to CEO, effective Feb. 1. He succeeds co-founder and CEO Alexey Margolin, who will become chairman.

Dermatology company Almirall S.A. (Madrid:ALM) hired Francesca Domenech Wuttke as chief digital officer and a director. She was managing director and investment principal Europe for the Global Health Innovation Fund of the venture arm of Merck & Co. Inc. (NYSE:MRK).

Amneal Pharmaceuticals Inc. (NYSE:AMRX) hired David Buchen as SVP, chief legal officer and corporate secretary, a newly expanded role at the generics and biologics company. He succeeds Sheldon Hirt, who held the previous version of the role as SVP, general counsel. Buchen was EVP of commercial, North American generics and international at Actavis plc, now Allergan plc (NYSE:AGN). Hirt will remain a director until the end of January.

Therapeutic protein engineering company Amunix Pharmaceuticals Inc. (Mountain View, Calif.) hired Angie You...

Read the full 1265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >